Stealth Biotherapeutics reports ‘positive’ results for elamipretide

Stealth BioTherapeutics recently presented positive results from its ophthalmic programs in dry age-related macular degeneration and Leber’s hereditary optic neuropathy. The data, which were presented at the Association for Research in Vision and Ophthalmology 2019 Annual Meeting, being held April 28 – May 2 in Vancouver, British Columbia, demonstrated significant improvements in visual function following treatment with elamipretide, an investigational drug, in its ReCLAIM study of patients with dry AMD and in the open-label portion of its ReSIGHT study of patients with LHON.
https://thefly.com/landingPageNews.php?id=2900419